

Liquid Biopsy Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

<https://marketpublishers.com/r/L6E428B8A92EN.html>

Date: December 2017

Pages: 120

Price: US\$ 2,750.00 (Single User License)

ID: L6E428B8A92EN

Abstracts

Liquid Biopsy Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Overview: Liquid biopsy is a minimally or non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. These tests have considerable potential for early detection of cancer, treatment and recurrence monitoring, detection of genetic abnormalities in fetus, and graft rejection in transplantation patients. According to the estimation of National Cancer Institute, in the US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths are estimated in 2016. While in Europe 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.

The liquid biopsy market is booming due to the rising prevalence of cancer globally, advanced maternal age leading to growing chromosomal aberrations, and the increasing preference of non-invasive liquid biopsy tests over invasive tissue biopsy. The lack of sensitivity and specificity of liquid biopsy tests, high cost of the test with fewer reimbursement facilities, and the lack of trained professionals are some of the factors hampering the market growth. The markets in emerging countries are expected to grow at a rapid pace during the forecast period due to the increasing disease prevalence, healthcare awareness, and healthcare spending.

Market Analysis: The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017–2023. The market is analyzed based on three

segments, namely biomarker type, sample type, application, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the liquid biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Biomarker Type Analysis: The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment is the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology.

Sample Type Analysis: The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupies the major market share in 2016 since most of the tests currently available in the market are blood-based tests.

Application Analysis: The global liquid biopsy market by application is segmented into cancer and non-cancer applications. Cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecasted period. Cancer application is further segmented by cancer indication and clinical application.

End-users Analysis: The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.

Key Players: Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.

Competitive Analysis: Currently, cancer tests dominate the global liquid biopsy market. A lot of new players are concentrating on this market to provide ground-breaking test with high sensitivity, specificity, and less turnaround time. Major market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, the major players are launching innovative tests to have an upper hand in the market. For instance, in September 2017,

Biocept launched Liquid Biopsy test for NRAS mutations.

Benefits: The report provides complete details about the usage and adoption rate of liquid biopsy tests in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding their business in this market.

Key Stakeholders:

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry overview
- 1.2 Total addressable market
- 1.3 Industry Trends

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Importance of Cell-Free DNA testing
- 3.3 Complications of Cell-Free DNA testing
- 3.4 Segmented Addressable Market (SAM)
- 3.5 Industry Trends
- 3.6 Related Markets
 - 3.6.1 Liquid biopsy market
 - 3.6.2 Transplantation Diagnostics Market

4 MARKET OUTLOOK

- 4.1 Overview
- 4.2 Regulatory framework
- 4.3 Funding scenario
- 4.4 Market segmentation
- 4.5 PEST Analysis
- 4.6 Porter 5(Five) Forces

5 MARKET CHARACTERISTICS

- 5.1 DRO – Global Cell-free DNA testing Market Dynamics
 - 5.1.1 Drivers

5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies

5.1.1.2 Rising number of cancers

5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis

5.1.2 Opportunities

5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries

5.1.2.2 Increase in mergers & acquisitions

5.1.3 Restraints

5.1.3.1 High test cost with less reimbursement facilities

5.1.3.2 Ethical issues

5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing

6 TEST TYPES: MARKET SIZE AND ANALYSIS

6.1 Overview

6.2 Non-invasive prenatal tests (NIPT)

6.3 Circulating tumour DNA tests

6.4 Donor-derived cell free DNA tests

7 APPLICATION: MARKET SIZE AND ANALYSIS

7.1 Overview

7.2 Prenatal testing

7.3 Cancer

7.4 Transplantation diagnostics

8 REGIONS: MARKET SIZE AND ANALYSIS

8.1 Overview

8.2 North America

8.2.1 Overview

8.2.2 United states

8.2.3 Canada

8.3 Europe

8.3.1 Overview

8.3.2 United Kingdom

8.3.3 Germany

8.3.4 France

8.3.5 Spain

8.4 APAC

8.4.1 Overview

8.4.2 India

8.4.3 China

8.5 Rest of the World

8.5.1 Overview

8.5.2 Brazil

8.5.3 Middle East

9 COMPETITIVE LANDSCAPE

9.1 Overview

10 VENDOR PROFILES

10.1 Natera, Inc.

10.1.1 Overview

10.1.2 Natera Inc.: Product offerings

10.1.3 NATERA, INC.: Recent Developments

10.1.4 Geographic Presence

10.1.5 Business Focus

10.1.6 SWOT Analysis

10.1.7 Business Strategy

10.2 Laboratory Corporation of America Holdings (LABCORP)

10.2.1 Overview

10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings

10.2.3 Laboratory Corporation Of America Holdings: Recent Developments

10.2.4 Business Unit

10.2.5 Geographic Presence

10.2.6 Business Focus

10.2.7 SWOT Analysis

10.2.8 Business Strategy

10.3 Illumina, Inc.,

10.3.1 Overview

10.3.2 Illumina, INC: Product offerings

10.3.3 Illumina, INC: Recent Developments

10.3.4 Geographic Presence

- 10.3.5 Business Focus
- 10.3.6 SWOT Analysis
- 10.3.7 Business Strategy
- 10.4 BEIJING GENOMICS INSTITUTE
 - 10.4.1 Overview
 - 10.4.2 Beijing Genomics Institute: Product offerings
 - 10.4.3 Beijing Genomics Institute: Recent Developments
 - 10.4.4 Business Focus
 - 10.4.5 SWOT Analysis
 - 10.4.6 Business Strategy
- 10.5 F.Hoffmann-La Roche Ltd
 - 10.5.1 Overview
 - 10.5.2 F. Hoffmann-la Roche: Product Offerings
 - 10.5.3 F. Hoffmann-la roche.: Recent Developments
 - 10.5.4 Business Unit
 - 10.5.5 Geographic Presence
 - 10.5.6 Business Focus
 - 10.5.7 SWOT Analysis
 - 10.5.8 Business Strategy
- Companies to Watch For
- 10.6 CareDx, Inc
 - 10.6.1 Overview
 - 10.6.2 caredx: Recent Developments
- 10.7 LifeCodexx AG
 - 10.7.1 Overview
 - 10.7.2 LifeCodexx AG: Recent Developments
- 10.8 Biocept, Inc.
 - 10.8.1 Overview
 - 10.8.2 Biocept, Inc.: Recent Developments
- 10.9 Quest Diagnostics
 - 10.9.1 Overview
 - 10.9.2 Quest Diagnostics: Recent Developments
- 10.10 Guardant Health
 - 10.10.1 Overview
 - 10.10.2 Guardant Health: Recent Developments
- 10.11 Inivata Limited
 - 10.11.1 Overview
 - 10.11.2 Inivata Limited: Recent Developments
- 10.12 Personal Genome Diagnostics

- 10.12.1 Overview
- 10.12.2 Personal Genome Diagnostics: Recent Developments
- 10.13 Trovagene
 - 10.13.1 Overview
 - 10.13.2 Trovagene, Inc.: Recent Developments
- Annexure
- Abbreviations

Tables

- Table 1 FUNDING SCENARIO
- Table 2 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPES, 2016–2023 (\$MILLION)
- Table 3 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION, 2016–2023 (\$MILLION)
- Table 4 GLOBAL CELL-FREE DNA TESTING MARKET REVENUE BY REGIONS, 2016–2023 (\$MILLION)
- Table 5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET BY VENDOR RANKING, 2016
- Table 6 OTHER PROMINENT VENDORS OF CELL-FREE DNA TESTING MARKET
- Table 7 CAREDX, INC.: SNAPSHOT
- Table 8 LIFECODEXX AG.: SNAPSHOT
- Table 9 BIOCEPT, INC.: SNAPSHOT
- Table 10 QUEST DIAGNOSTICS: SNAPSHOT
- Table 11 GUARDANT HEALTH INC.: SNAPSHOT
- Table 12 INIVATA LIMITED: SNAPSHOT
- Table 13 PERSONAL GENOME DIAGNOSTICS: SNAPSHOT
- Table 14 TROVAGENE, INC.: SNAPSHOT

Charts

- Chart 1 RESEARCH METHODOLOGY OF GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 2 WORLDWIDE CELL-FREE DNA TESTING MARKET REVENUE, 2016–2023 (\$MILLION)
- Chart 3 PEST ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 4 PORTER 5 FORCES ON GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
- Chart 6 KEY STAKEHOLDERS
- Chart 7 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2016 (%)

Chart 8 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE
SEGMENTATION, 2023 (%)

Chart 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE
FORECAST,

2016–2023 (\$MILLION)

Chart 10 GLOBAL CIRCULATING TUMOUR DNA MARKET REVENUE FORECAST,
2016–2023 (\$MILLION)

Chart 11 GLOBAL DONOR-DERIVED CELL-FREE DNA TESTING MARKET
REVENUE FORECAST, 2016–2023 (\$MILLION)

Chart 12 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION
SEGMENTATION, 2016 (%)

Chart 13 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION
SEGMENTATION, 2023 (%)

Chart 14 GLOBAL CELL-FREE DNA TESTING MARKET BY GEOGRAPHICAL
SEGMENTATION, 2016 (%)

Chart 15 CELL-FREE DNA TESTING MARKET REVENUE IN NORTH AMERICA,
2016–2023 (\$MILLION)

Chart 16 CELL-FREE DNA TESTING MARKET REVENUE IN EUROPE, 2016–2023
(\$MILLION)

Chart 17 CELL-FREE DNA TESTING MARKET REVENUE IN ASIA-PACIFIC,
2016–2023 (\$MILLION)

Chart 18 CELL-FREE DNA TESTING MARKET REVENUE IN REST OF THE WORLD,
2016–2023 (\$MILLION)

Chart 19 NATERA: OVERVIEW SNAPSHOT

Chart 20 NATERA: GEOGRAPHIC PRESENCE

Chart 21 NATERA: SWOT ANALYSIS

Chart 22 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW
SNAPSHOT

Chart 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS
UNITS

Chart 24 LABORATORY CORPORATION OF AMERICA HOLDINGS:
GEOGRAPHICAL PRESENCE

Chart 25 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT
ANALYSIS

Chart 26 ILLUMINA, INC: OVERVIEW SNAPSHOT

Chart 27 ILLUMINA, INC: GEOGRAPHIC PRESENCE

Chart 28 ILLUMINA, INC: SWOT ANALYSIS

- Chart 29 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS
- Chart 30 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
- Chart 31 F. HOFFMANN-LA ROCHE: BUSINESS UNITS
- Chart 32 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
- Chart 33 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS

I would like to order

Product name: Liquid Biopsy Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023

Product link: <https://marketpublishers.com/r/L6E428B8A92EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L6E428B8A92EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

